Gossamer Bio, Inc. (GOSS): Net Income
-$170.37M
Year ended 2025-12-31
-$125.22M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$170.37M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$56.53M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$179.82M | n/m | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | -$229.38M | n/m | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | -$234.00M | n/m | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | -$243.36M | n/m | 2023-03-17, From 2020-01-01 |
| 2019-12-31 | -$180.31M | n/m | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | -$146.97M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | -$6.77M | n/a | 2020-03-24, From 2017-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$170.37M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$50.34M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | -$130.15M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | -$48.88M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$265.94M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$83.78M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | -$2.84M | n/m |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | -$2.84M | n/m |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$35.04M | n/m |
Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗